Glenmark settles pending litigation over patent in US

Our Bureau Mumbai | Updated on November 06, 2012

Glenmark Generics Inc, USA, the US subsidiary of Glenmark Generics Ltd, has announced the settlement of litigation pending between Glenmark and Janssen Pharmaceuticals over patent actions concerning Norgestimate and Ethinyl Estradiol tablets. The latter comprises the generic version of Janssen Ortho Tri-cyclen Lo tablets.

Under the terms of the settlement agreements, Glenmark will be able to market and distribute its Norgestimate and Ethinyl Estradiol tablets under a royalty-bearing licence from Janssen on December 31, 2015, or earlier under certain circumstances.

Janssen currently markets its product as Ortho Tri-cyclen Lo in the US, indicated for the prevention of pregnancy in women who elect to use oral contraceptives as a method of contraception.

Total US sales as reported by IMS Health for the 12-month period ending June 2012 were approximately $397 million.

Published on November 06, 2012

Follow us on Telegram, Facebook, Twitter, Instagram, YouTube and Linkedin. You can also download our Android App or IOS App.

This article is closed for comments.
Please Email the Editor

You May Also Like